Zoledronic Acid Inhibits Both the Osteolytic and Osteoblastic Components of Osteosarcoma Lesions in a Mouse Model

Por Labrinidis, Agatha, Hay, Shelley, Liapis, Vasilios, Ponomarev, Vladimir, Findlay, David M., Evdokiou, Andreas
Publicado no Clin Cancer Res (2009)

Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males

Por Findlay, David, Chehade, Mellick, Tsangari, Helen, Neale, Susan, Hay, Shelley, Hopwood, Blair, Pannach, Susan, O'Loughlin, Peter, Fazzalari, Nicola
Publicado em 2008

Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo

Por Zinonos, Irene, Labrinidis, Agatha, Lee, Michelle, Liapis, Vasilios, Hay, Shelley, Ponomarev, Vladimir, Diamond, Peter, Findlay, David M, Zannettino, Andrew CW, Evdokiou, Andreas
Publicado no J Bone Miner Res (2011)

Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer

Por Zinonos, Irene, Labrinidis, Agatha, Lee, Michelle, Liapis, Vasilios, Hay, Shelley, Ponomarev, Vladimir, Diamond, Peter, Zannettino, Andrew C.W., Findlay, David M., Evdokiou, Andreas
Publicado no Mol Cancer Ther (2009)

Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer...

Por Zysk, Aneta, DeNichilo, Mark O., Panagopoulos, Vasilios, Zinonos, Irene, Liapis, Vasilios, Hay, Shelley, Ingman, Wendy, Ponomarev, Vladimir, Atkins, Gerald, Findlay, David, Zannettino, Andrew, Evdokiou, Andreas
Publicado no Cancer Lett (2016)

HYPOXIA-ACTIVATED PRO-DRUG TH-302 EXHIBITS POTENT TUMOUR SUPPRESSIVE ACTIVITY AND COOPERATES WITH CHEMOTHERAPY AGAINST OSTEOSARCOMA

Por Liapis, Vasilios, Labrinidis, Agatha, Zinonos, Irene, Hay, Shelley, Ponomarev, Vladimir, Panagopoulos, Vasilios, DeNichilo, Mark, Ingman, Wendy, Atkins, Gerald J., Findlay, David M., Zannettino, Andrew CW., Evdokiou, Andreas
Publicado no Cancer Lett (2014)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models

Por Liapis, Vasilios, Zinonos, Irene, Labrinidis, Agatha, Hay, Shelley, Ponomarev, Vladimir, Panagopoulos, Vasilios, Zysk, Aneta, DeNichilo, Mark, Ingman, Wendy, Atkins, Gerald J., Findlay, David M., Zannettino, Andrew C. W., Evdokiou, Andreas
Publicado no Cancer Med (2016)

Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma

Por Labrinidis, Agatha, Diamond, Peter, Martin, Sally, Hay, Shelley, Liapis, Vasilios, Zinonos, Irene, Sims, Natalie A., Atkins, Gerald J., Vincent, Cristina, Ponomarev, Vladimir, Findlay, David M., Zannettino, Andrew C.W., Evdokiou, Andreas
Publicado no Clin Cancer Res (2009)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma

Por Liapis, Vasilios, Zysk, Aneta, DeNichilo, Mark, Zinonos, Irene, Hay, Shelley, Panagopoulos, Vasilios, Shoubridge, Alexandra, Difelice, Christopher, Ponomarev, Vladimir, Ingman, Wendy, Atkins, Gerald J., Findlay, David M., Zannettino, Andrew C. W., Evdokiou, Andreas
Publicado no Cancer Med (2017)

Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer

Por ZINONOS, IRENE, LUO, KE-WANG, LABRINIDIS, AGATHA, LIAPIS, VASILIOS, HAY, SHELLEY, PANAGOPOULOS, VASILIOS, DENICHILO, MARK, KO, CHUN-HAY, YUE, GRACE GAR-LEE, LAU, CLARA BIK-SAN, INGMAN, WENDY, PONOMAREV, VLADIMIR, ATKINS, GERALD J., FINDLAY, DAVID M., ZANNETTINO, ANDREW C.W., EVDOKIOU, ANDREAS
Publicado em 2014